纳地美定导致的不良反应怎么治疗？

Introduction: Nadimedin is marketed under the brand name Symproic in the United States and Rizmoic in the European Union, and is used in the European Union to treat opioid-induced constipation in adults who have been treated with laxatives, or in the United States to treat opioid-induced constipation in adults with chronic non-cancer pain. Naldimedine is a peripherally acting μ-opioid receptor antagonist developed and produced by Shionogi Pharmaceutical Co., Ltd. of Japan.

Adverse reactions caused by naldimedine

Possible adverse reactions include the following.

1. Allergic reaction: If symptoms such as rash, hives, difficulty breathing, swelling of the face, lips, tongue or throat occur, seek emergency medical help immediately.

2. Opioid withdrawal symptoms: include sweating, fever, chills, warm or tingling sensation in the face, tremors, rapid heartbeat, anxiety or agitation, yawning, runny nose, sneezing, watery eyes, stomach pain, nausea, vomiting and diarrhea.

3. Gastrointestinal perforation: Severe stomach pain may be a sign of a serious disease. If persistent stomach pain occurs, please stop taking Nadimedine immediately and seek emergency medical help.

Also includes nausea, vomiting, stomach pain, diarrhea, fever, rash, itching, hoarseness, sweating, indigestion, etc. If adverse reactions occur while using nadimedine, you should contact a medical professional promptly.

How to treat adverse reactions caused by naldimedine

1. Gastrointestinal discomfort: Ensure a light diet, avoid eating heavy and irritating foods, pay attention to dietary fiber intake, and ensure adequate water intake. If symptoms are severe or persistent, it is recommended to consult a doctor, who may need to adjust the dose or choose an alternative medication.

2. Dehydration: Drink more water and maintain adequate fluid intake. Avoid heavy drinking or drinks with high caffeine content.

The above treatment measures can help deal with the side effects of naldimedine, but the most important thing is to maintain close communication with your doctor in order to respond to side effects in a timely manner and obtain appropriate treatment and treatment suggestions.

Use of naldimedine in special populations

1. Children: The safety and effectiveness of naldimedine have not been determined in pediatric patients.

2. Elderly patients: Among the 1,163 patients exposed to naldimedine in clinical studies, 183 (16%) were 65 years and above, and 37 (3%) were 75 and above. No overall differences in safety or efficacy were observed between these patients and younger patients, although greater sensitivity in some older individuals cannot be ruled out.

3. Patients with liver damage: The impact of severe liver damage on the pharmacokinetics of naldimedine has not been evaluated. Patients with severe liver damage should avoid using naldimedine. Patients with mild or moderate liver damage need to use naldimedine without dose adjustment.